Toxicity of a combined therapy using the mTOR-inhibitor everolimus and PRRT with [(177)Lu]Lu-DOTA-TATE in Lewis rats

PURPOSE: Peptide receptor radionuclide therapy (PRRT) with [(177)Lu]Lu-DOTA(0),TYR(3)-octreotate ([(177)Lu]Lu-DOTA-TATE) and the mechanistic target of rapamycin (mTOR) inhibitor everolimus are both approved for the treatment of neuroendocrine tumours (NET). However, tumour progression is still frequ...

Descripción completa

Detalles Bibliográficos
Autores principales: Zellmer, Johannes, Yen, Hsi-Yu, Kaiser, Lena, Mille, Erik, Gildehaus, Franz Josef, Böning, Guido, Steiger, Katja, Hacker, Marcus, Bartenstein, Peter, Todica, Andrei, Haug, Alexander R., Ilhan, Harun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183514/
https://www.ncbi.nlm.nih.gov/pubmed/32335736
http://dx.doi.org/10.1186/s13550-020-00628-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183514/
https://www.ncbi.nlm.nih.gov/pubmed/32335736
http://dx.doi.org/10.1186/s13550-020-00628-y

Ejemplares similares